Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1871763417
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
5
Medicare group memberships
Hospitals
5
Hospital affiliations
6445 Main Street, Opc 24
Houston, TX, 77030
Phone (713) 441-9948
Groups this clinician bills Medicare through
Medicare paid, 2024
$72K
909 services
Medicare patients, 2024
199
Average age 76
Drug cost, 2024
$4.6M
1,235 prescriptions
Company payments, 2025
$1,078
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shilpan S Shah was code 99214 (office e&m - established), 272 times for 83 patients. In total Shilpan S Shah billed 909 services in 14 codes, and Medicare paid $72K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-10-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 272 | 83 | $95.50 | $26K |
| 99233 Hospital E&M - Subsequent | Facility | 155 | 50 | $92.63 | $14K |
| 99213 Office E&M - Established | Office | 151 | 87 | $64.90 | $9,800 |
| 99232 Hospital E&M - Subsequent | Facility | 118 | 59 | $62.80 | $7,410 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 80 | 34 | $13.13 | $1,050 |
| 99221 Hospital E&M - Initial | Facility | 37 | 31 | $64.79 | $2,397 |
| 99215 Office E&M - Established | Office | 24 | 18 | $123.80 | $2,971 |
| 38222 Other Organ Systems | Office | 18 | 15 | $131.13 | $2,360 |
| 99222 Hospital E&M - Initial | Facility | 16 | 16 | $103.59 | $1,657 |
| 99204 Office E&M - New | Office | 12 | 12 | $115.85 | $1,390 |
By year: 2022 $84K for 978 services; 2023 $72K for 781 services; 2024 $72K for 909 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shilpan S Shah prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 149 prescriptions and refills. In total Shilpan S Shah wrote 1,235 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 149 | 235 | 49 | $8,292 |
| Venclexta Venetoclax | 94 | 94 | 24 | $323K |
| Acyclovir Generic | 75 | 119 | 22 | $1,030 |
| Fluconazole Generic | 70 | 76 | 24 | $1,869 |
| Prednisone Generic | 69 | 76 | 17 | $219 |
| Ondansetron Odt Ondansetron | 60 | 60 | 31 | $645 |
| Eliquis Apixaban | 59 | 71 | 12 | $38K |
| Inqovi Decitabine/Cedazuridine | 52 | 52 | Under 11 | $420K |
| Hydroxyurea Generic | 47 | 74 | 11 | $769 |
| Dexamethasone Generic | 44 | 47 | 13 | $512 |
| Levofloxacin Generic | 34 | 34 | 15 | $361 |
| Sprycel Dasatinib | 31 | 31 | Under 11 | $368K |
| Doxycycline Hyclate Generic | 27 | 33 | 12 | $1,065 |
| Allopurinol Generic | 26 | 46 | 13 | $169 |
| Lenalidomide Generic | 25 | 25 | Under 11 | $319K |
Brand drugs: 387 claims; generic drugs: 848 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shilpan S Shah $1,078 ($1,078 in general payments such as food, travel and fees) from 16 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $340.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $340 |
| Daiichi Sankyo Inc. 4568.T | 5 | $125 |
| Pfizer Inc. PFE | 4 | $124 |
| Adaptive Biotechnologies Corporation ADPT | 2 | $67.25 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $59.48 |
| Sobi, Inc SOBI.ST | 2 | $58.55 |
| Janssen Biotech, Inc. JNJ | 2 | $57.91 |
| Abbvie Inc. ABBV | 2 | $52.74 |
| Incyte Corporation INCY | 2 | $39.51 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $32.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.